Research Projects & Grants

• Randomized clinical trial assessing the effects of Pneumatic Vitreolysis on Vitreomacular traction (Protocol AG), Role: Investigator, (07/2019 - 07/2020) Status: Completed
• Single-arm study assessing the effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH), Role: Investigator, Status: Completed

College/University

• SCORE2 Comparative Trial, Role: Principal Investigator, Pennsylvania State University, (09/2013 - 03/2016) Status: Closed
• Standard Care Versus Corticosteroid for Retinal Occlusion (SCORE), Role: Principal Investigator, University of Wisconsin-Madison, (12/2004 - 04/2009) Status: Closed

Federal

• Genetics in retinal diseases project, Role: Investigator, National Eye Institute/NIH/DHHS, (10/2024 - 10/2025) Status: Approved
• Intravitreous Anti-VEGF treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk, Role: Investigator, National Eye Institute/NIH/DHHS, (04/2022 - 04/2023) Status: Completed
• Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy, Role: Investigator, National Eye Institute/NIH/DHHS, (01/2019 - 01/2020) Status: Completed
• A phase II evaluation of topical NSAIDs in eyes with non central involved DME, Role: Investigator, National Eye Institute/NIH/DHHS, (03/2015 - 03/2016) Status: Completed
• (MAS) Diabetic Retinopathy Clinical Research Network (DRCR), Role: Other Professional, Jaeb Center for Health Research, (03/2013 - 03/2025) Status: Awarded
• Intravitreal ranibizumab or triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy, Role: Investigator, National Eye Institute/NIH/DHHS, (01/2013 - 01/2014) Status: Completed
• Age-related eye disease study 2 (AREDS 2): a multi-center, randomized trial of Lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] in age-related macular degeneration, Role: PI, National Eye Institute/NIH/DHHS, (12/2012 - 12/2013) Status: Completed
• A pilot study in individuals with center-involved DME undergoing cataract surgery (Protocol P), Role: Investigator, National Eye Institute/NIH/DHHS, (08/2012 - 08/2013) Status: Completed
• An observational study in individuals with diabetic retinopathy without center-involved DME undergoing cataract surgery (Protocol Q), Role: Investigator, National Eye Institute/NIH/DHHS, (08/2012 - 08/2013) Status: Completed
• Subclinical diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2009 - 11/2010) Status: Completed
• A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (05/2009 - 05/2010) Status: Completed
• A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (avastin), Role: Investigator, National Eye Institute/NIH/DHHS, (01/2009 - 01/2010) Status: Completed
• The standard care versus corticosteroid for retinal vein occlusion (SCORE) study: Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: One for central retinal vein occlusion and one for branch retinal vein occlusion, Role: PI, National Eye Institute/NIH/DHHS, (11/2008 - 11/2009) Status: Completed
• A pilot study of peribulbar triamcinolone acetonide for diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2007 - 11/2008) Status: Completed
• An observational study of the development of diabetic macular edema following scatter laser photocoagulation, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2007 - 11/2008) Status: Completed
• Randomized trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + deferred Aflibercept for treatment of central-involved diabetic macular edema (Protocol AC), Role: Investigator, National Institute on Minority Health and Health Disparities/NIH/DHHS, Status: Completed
• Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ), Role: Investigator, Jaeb Center for Health Research, Status: Completed
• A phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN), Role: Investigator, Jaeb Center for Health Research, Status: Completed

For Profit Organization

• A prospective, multicenter clinical study of the implantable miniature telescope, model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD), Role: PI, Samsara Vision, Inc, (08/2024 - 08/2025) Status: Approved
• Prospective, multicenter, post-approval, registry study to assess 5-year safety of the implantable miniature telescope for the treatment of vision impairment associated with end-stage, age-related macular degeneration, Role: PI, VisionCare, Inc, (03/2025 - 03/2026) Status: Approved
• A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD), Role: PI, NGM Biopharmaceuticals, Inc., (10/2022 - 10/2023) Status: Completed
• A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON), Role: PI, Novartis Pharmaceuticals Corporation, (08/2022 - 08/2023) Status: Completed
• A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema, Role: PI, Unity Biotechnology, Inc., (06/2022 - 06/2023) Status: Completed
• A prospective, multicenter clinical trial of the implantable miniature telescope in pseudophakic eyes with central vision impairment associated with end-stage macular degeneration., Role: PI, VisionCare, Inc, (05/2021 - 05/2022) Status: Completed
• A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER), Role: PI, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
• A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study), Role: Investigator, Graybug Vision, Inc., (09/2020 - 08/2021) Status: Completed
• A phase 2/3, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION), Role: PI, Quark Pharmaceuticals, (01/2019 - 01/2020) Status: Completed
• The efficacy and safety of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension, Role: PI, Allergan Inc., (01/2019 - 01/2020) Status: Completed
• Safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration, Role: Investigator, Allergan Inc., (09/2018 - 09/2019) Status: Completed
• A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study, Role: PI, Novartis Pharmaceuticals Corporation, (07/2018 - 07/2019) Status: Completed
• A two-year, randomized, double-masked, multi-center, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration, Role: Investigator, Alcon Research Inc., (02/2018 - 02/2019) Status: Completed
• A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab (FCFD4514S) in patients with geographic atrophy who have completed Genentech-sponsored lampalizumab studies, Role: Investigator, Genentech, Inc., (09/2017 - 09/2018) Status: Completed
• A comparative effectiveness study of intravitreal aflibercept, bevacizumab for diabetic macular edema (protocol T), Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (08/2017 - 08/2018) Status: Completed
• Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes (protocol U), Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (04/2017 - 04/2018) Status: Completed
• A phase II, multicenter, randomized, single-masked, sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy, Role: Investigator, Genentech, Inc., (10/2016 - 10/2017) Status: Completed
• A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation, Role: Investigator, Vertex Pharmaceuticals Incorporated (Vertex), (05/2014 - 05/2015) Status: Completed
• Home vision monitoring in AREDS2 for progression to neovascular AMD using the ForeseeHome device, Role: PI, Notal Vision, (07/2013 - 07/2014) Status: Completed
• Case cross-over study of PDE5 inhibitor exposure as a potential "trigger factor" for acute naion, Role: PI, Pfizer Pharmaceuticals, (07/2012 - 07/2013) Status: Completed
• Evaluation of visual acuity measurements in eyes with diabetic macular edema - protocol L, Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (05/2012 - 05/2013) Status: Completed
• A Phase 2B Dose-Ranging Study of Pazopanib Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration (AMD), Role: Investigator, GlaxoSmithKline, (02/2012 - 02/2013) Status: Completed
• A Randomized, Single-Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (07/2011 - 07/2012) Status: Completed
• A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2011 - 04/2012) Status: Completed
• FVF3426g: An open-label, multi-center extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech sponsored ranibizumab study, Role: Investigator, Genentech, Inc., (03/2010 - 03/2011) Status: Completed
• A phase III, mulicenter, randomized, sham injection-controlled study of the efficacy and safety of ranizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion, Role: Investigator, Genentech, Inc., (05/2009 - 05/2010) Status: Completed
• A phase III, mulicenter, randomized, sham injection-controlled study of the efficacy and safety of ranizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion, Role: Investigator, Genentech, Inc., (05/2008 - 05/2009) Status: Completed
• A pilot study of laser photocoagulation for diabetic macular edema, Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (04/2008 - 04/2009) Status: Completed
• An exploratory study of the safety, tolerability and biological effect of intravitreal administration of VEGF trap in patients with neovascular age-related macular degeneration [VGFT-OD-0502.00 04/07/2005; Investigator's Brochure Edition 1 04/05/05], Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2008 - 04/2009) Status: Completed
• A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion, Role: Investigator, Allergan Inc., (03/2008 - 03/2009) Status: Completed
• Pretreatment with ketorolac tromethamine for diabetics undergoing cataract surgery., Role: PI, Allergan Inc., (10/2007 - 10/2008) Status: Completed
• A randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF trap in patients with neovascular age-related macular degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2007 - 04/2008) Status: Completed
• A phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of ranibizumab in subfoveal choroidal neovascularization (CNV) with or without classic CNV secondary to age-related macular degeneration [FVF3192g protocol date:6/4/2004], Role: Investigator, Genentech, Inc., (07/2006 - 07/2007) Status: Completed
• MSI-1256F-209- A phase 2, multi-center, randomized, masked, controlled, study of MSI-1256F (Squalamine lactate) for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration, Role: PI, Genaera Corporation, (04/2006 - 03/2007) Status: Completed
• True drop eye drop study, Role: Investigator, JF Scientific Industries, Inc., (05/2004 - 05/2005) Status: Completed

Internal

• Cataract surgery and intraocular lens and Artificial Intelligence, Role: Investigator, LLU Dept. of Ophthalmology, (07/2024) Status: Approved
• Patient Satisfaction With The Vivity Intraocular Lens, Role: PI, LLU Dept. of Ophthalmology, (05/2023) Status: Approved
• Retrospective Review of Management of Open Globe Injuries Before and After Implementation of Standardized Harvard Protocol and Order-Set, Role: PI, LLU Dept. of Orthodontics, (02/2022) Status: Approved
• Effect of PanOptix trifocal intraocular lens on standard automated perimetry results, Role: Investigator, LLU Dept. of Ophthalmology, (04/2021) Status: Approved
• Patient Satisfaction With The Symfony Intraocular Lens, Role: PI, LLU Dept. of Ophthalmology, (03/2021) Status: Approved
• Effect of Hypochlorous Acid Disinfection on Ocular Flora Prior to Cataract Surgery, Role: Investigator, LLU Dept. of Ophthalmology, (09/2020) Status: Completed
• Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections, Role: Investigator, LLU Dept. of Ophthalmology, (03/2020) Status: Approved
• Anterior chamber depth to axial length ratio as a predictor of post-surgical refractive outcome following uncomplicated cataract surgery, Role: Investigator, LLU Dept. of Ophthalmology, (05/2019) Status: Approved
• Efficacy of triamcinolone acetonide/moxifloxacin compound drug in cataract surgery of vitrectomized eyes, Role: PI, LLU Dept. of Ophthalmology, (05/2019) Status: Completed
• Conjunctival floral resistance in a single practice site comparing povidone-iodine prep with or without post-injection second generation fluoroquinolones, Role: PI, LLU Dept. of Ophthalmology, (07/2018 - 07/2019) Status: Completed
• Retrospective analysis of pars plana trimoxi injection for dropless cataract surgery, Role: PI, LLU Dept. of Ophthalmology, (07/2018 - 07/2019) Status: Completed
• Patient satisfaction with dropless cataract surgery versus conventional cataract surgery, Role: PI, LLU Dept. of Ophthalmology, (04/2018 - 04/2019) Status: Completed
• A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 µg/day and ASI-0010B 0.2 µg/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema, Role: PI, LLU Dept. of Ophthalmology, (08/2010 - 08/2011) Status: Completed
• Comparing the near and intermediate visual acuity with the acrysof SN60WF and SA60AT, Role: Investigator, LLU Dept. of Ophthalmology, (01/2010 - 01/2011) Status: Completed
• (INT) Residual - Ophthalmology, Role: Principal Investigator, LLU Dept. of Ophthalmology, (02/2009 - 06/2027) Status: Awarded
• Anterior capsule contraction syndrome with the AcrySof SA60AT Acrylic lens, Role: PI, LLU Dept. of Ophthalmology, (10/2007 - 10/2008) Status: Completed
• Change in macular thickness after cataract surgery as measured by optical coherence tomography, Role: PI, LLU Dept. of Ophthalmology, (06/2007 - 06/2008) Status: Completed
• Comparison of Technis Z9000 Introcular Lens (IOL) with Acrysof IOL with regards to higher order aberrations and visual acuity, Role: Investigator, LLU Dept. of Ophthalmology, (09/2003 - 09/2004) Status: Completed

Non-Profit Organization

• Intravitreous anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy (protocol AB), Role: Investigator, National Institute for Health Care Management Research and Educational Foundation, (03/2020 - 03/2021) Status: Completed
• A phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus, Role: Investigator, Genentech Foundation for Growth and Development, (04/2011 - 04/2012) Status: Completed